FDA warned Lipotriad LLC that its eye vitamins are unapproved new drugs and misbranded due to disease-prevention claims online.
What happened
FDA reviewed Lipotriad's website and Facebook and Twitter pages in November 2020. FDA found claims that the eye vitamin products prevent or treat diseases such as macular degeneration, cataracts, glaucoma, blindness, and dry eye, making them drugs. FDA also said the products are unapproved new drugs and misbranded because they lack adequate directions for those disease uses.
What FDA found
Website and social media claims that the eye vitamins prevent or treat eye diseases make the products drugs.
FD&C Act section 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]The products are unapproved new drugs because they are not generally recognized as safe and effective for the claimed disease uses.
FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]The products are misbranded because they lack adequate directions for use for their intended disease uses.
FD&C Act section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Selling the misbranded products in interstate commerce violates the Act.
FD&C Act section 301(a) [21 U.S.C. 331(a)]
What FDA wants
FDA asks Lipotriad to notify it in writing within 15 working days of receipt about steps taken to correct the violations and prevent recurrence, with supporting documents. If corrections cannot be completed in that time, the company must state why and give a completion timeframe.
Who should pay attention
- dietary supplement brands with eye-health claims
- companies making disease-prevention claims on websites or social media
- marketers of vitamins sold as supplements
This is a summary. Read the original letter on fda.gov.